vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and RE/MAX Holdings, Inc. (RMAX). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $71.1M, roughly 2.0× RE/MAX Holdings, Inc.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 2.0%, a 33.5% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -1.8%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $33.5M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -4.7%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
RE/MAX is an international real estate franchise operating in over 100 countries and territories that, in 2015, had over 100,000 agents in 6,800 offices.
ADMA vs RMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $71.1M |
| Net Profit | $49.4M | $1.4M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 13.1% |
| Net Margin | 35.5% | 2.0% |
| Revenue YoY | 18.4% | -1.8% |
| Net Profit YoY | -55.9% | -75.2% |
| EPS (diluted) | $0.20 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $71.1M | ||
| Q3 25 | $134.2M | $73.2M | ||
| Q2 25 | $122.0M | $72.8M | ||
| Q1 25 | $114.8M | $74.5M | ||
| Q4 24 | $117.5M | $72.5M | ||
| Q3 24 | $119.8M | $78.5M | ||
| Q2 24 | $107.2M | $78.5M | ||
| Q1 24 | $81.9M | $78.3M |
| Q4 25 | $49.4M | $1.4M | ||
| Q3 25 | $36.4M | $4.0M | ||
| Q2 25 | $34.2M | $4.7M | ||
| Q1 25 | $26.9M | $-2.0M | ||
| Q4 24 | $111.9M | $5.8M | ||
| Q3 24 | $35.9M | $966.0K | ||
| Q2 24 | $32.1M | $3.7M | ||
| Q1 24 | $17.8M | $-3.4M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 13.1% | ||
| Q3 25 | 38.0% | 25.0% | ||
| Q2 25 | 35.1% | 19.3% | ||
| Q1 25 | 30.4% | 7.2% | ||
| Q4 24 | 32.6% | 5.9% | ||
| Q3 24 | 33.1% | 19.4% | ||
| Q2 24 | 36.6% | 20.6% | ||
| Q1 24 | 26.7% | 5.8% |
| Q4 25 | 35.5% | 2.0% | ||
| Q3 25 | 27.1% | 5.4% | ||
| Q2 25 | 28.1% | 6.4% | ||
| Q1 25 | 23.4% | -2.6% | ||
| Q4 24 | 95.2% | 8.0% | ||
| Q3 24 | 30.0% | 1.2% | ||
| Q2 24 | 29.9% | 4.7% | ||
| Q1 24 | 21.7% | -4.3% |
| Q4 25 | $0.20 | — | ||
| Q3 25 | $0.15 | — | ||
| Q2 25 | $0.14 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.15 | — | ||
| Q2 24 | $0.13 | — | ||
| Q1 24 | $0.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $118.7M |
| Total DebtLower is stronger | $72.1M | $432.2M |
| Stockholders' EquityBook value | $477.3M | $452.4M |
| Total Assets | $624.2M | $582.5M |
| Debt / EquityLower = less leverage | 0.15× | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $118.7M | ||
| Q3 25 | $61.4M | $107.5M | ||
| Q2 25 | $90.3M | $94.3M | ||
| Q1 25 | $71.6M | $89.1M | ||
| Q4 24 | $103.1M | $96.6M | ||
| Q3 24 | $86.7M | $83.8M | ||
| Q2 24 | $88.2M | $66.1M | ||
| Q1 24 | $45.3M | $82.1M |
| Q4 25 | $72.1M | $432.2M | ||
| Q3 25 | $72.4M | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | $72.3M | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
| Q4 25 | $477.3M | $452.4M | ||
| Q3 25 | $431.2M | $448.1M | ||
| Q2 25 | $398.3M | $442.4M | ||
| Q1 25 | $373.4M | $433.5M | ||
| Q4 24 | $349.0M | $429.5M | ||
| Q3 24 | $231.9M | $423.1M | ||
| Q2 24 | $188.3M | $418.4M | ||
| Q1 24 | $153.7M | $412.0M |
| Q4 25 | $624.2M | $582.5M | ||
| Q3 25 | $568.7M | $582.2M | ||
| Q2 25 | $558.4M | $574.8M | ||
| Q1 25 | $510.6M | $571.4M | ||
| Q4 24 | $488.7M | $581.6M | ||
| Q3 24 | $390.6M | $578.6M | ||
| Q2 24 | $376.4M | $571.4M | ||
| Q1 24 | $350.9M | $566.7M |
| Q4 25 | 0.15× | 0.96× | ||
| Q3 25 | 0.17× | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | 0.21× | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $40.9M |
| Free Cash FlowOCF − Capex | $34.6M | $33.5M |
| FCF MarginFCF / Revenue | 24.8% | 47.1% |
| Capex IntensityCapex / Revenue | 0.8% | 10.4% |
| Cash ConversionOCF / Net Profit | 0.72× | 28.39× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $56.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $40.9M | ||
| Q3 25 | $13.3M | $17.7M | ||
| Q2 25 | $21.1M | $4.6M | ||
| Q1 25 | $-19.7M | $5.7M | ||
| Q4 24 | $50.2M | $59.7M | ||
| Q3 24 | $25.0M | $17.6M | ||
| Q2 24 | $45.6M | $15.9M | ||
| Q1 24 | $-2.2M | $9.4M |
| Q4 25 | $34.6M | $33.5M | ||
| Q3 25 | $-1.1M | $16.4M | ||
| Q2 25 | $18.7M | $2.9M | ||
| Q1 25 | $-24.4M | $4.0M | ||
| Q4 24 | $47.5M | $53.0M | ||
| Q3 24 | $24.0M | $16.3M | ||
| Q2 24 | $43.6M | $14.0M | ||
| Q1 24 | $-4.6M | $6.8M |
| Q4 25 | 24.8% | 47.1% | ||
| Q3 25 | -0.8% | 22.4% | ||
| Q2 25 | 15.3% | 4.0% | ||
| Q1 25 | -21.2% | 5.3% | ||
| Q4 24 | 40.4% | 73.2% | ||
| Q3 24 | 20.0% | 20.8% | ||
| Q2 24 | 40.7% | 17.8% | ||
| Q1 24 | -5.6% | 8.6% |
| Q4 25 | 0.8% | 10.4% | ||
| Q3 25 | 10.7% | 1.8% | ||
| Q2 25 | 2.0% | 2.2% | ||
| Q1 25 | 4.1% | 2.3% | ||
| Q4 24 | 2.3% | 9.1% | ||
| Q3 24 | 0.9% | 1.7% | ||
| Q2 24 | 1.9% | 2.4% | ||
| Q1 24 | 2.9% | 3.3% |
| Q4 25 | 0.72× | 28.39× | ||
| Q3 25 | 0.36× | 4.45× | ||
| Q2 25 | 0.62× | 0.97× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | 10.28× | ||
| Q3 24 | 0.70× | 18.22× | ||
| Q2 24 | 1.42× | 4.29× | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
